Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine

Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress
of Targeted Genetic Medicine
Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and
Pancreas Cancer as Stand-alone Therapy

SAN MARINO, Calif., Oct. 12 /PRNewswire/ -- Epeius Biotechnologies Corporation
today announced more stunning results of its pioneering clinical studies of
Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine
to be validated in the clinic. Administered as stand-alone therapy in
late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again
accomplished what standard cancer treatments and even much-touted biologics
have failed to do: that is, to bring forth the benefits of remission in
otherwise intractable metastatic cancers. Three recent cases of Stage IV
metastatic cancer, namely (i) osteosarcoma, (ii) prostate cancer, and (iii)
pancreas cancer, demonstrated that Rexin-G treatments alone led to clinical
remission of disease in each of these poor prognosis patients. Even more
remarkable, perhaps, are the profiles of the latter two patients, which
signal the advent of Rexin-G as the vanguard of a new class of exceedingly
precise, selective, and effective anti-cancer agents, and which typify a
newfound societal acceptance and acknowledgement of the real-world promise and
potential of this uniquely-targeted genetic medicine.

Remarkably, a Catholic priest, who was previously bedridden and in withering
pain, suffering from end-stage prostate cancer that had spread to his bones,
received successive courses of Rexin-G, during which time the bone pain was
relieved, the PSA tumor markers fell, the bone tumors stopped growing, and
even the previously inoperable primary tumor disappeared on follow-up CT
scans. As the priest's bones began to heal and strengthen, he arose from his
bed and is currently saying daily Mass and delivering lectures in the
seminary. What is even more remarkable is that this revered man of the cloth
was over ninety years old at the time of his treatment and remission. This
past week, the latest good news comes from the trenches of Stage IVb pancreas
cancer, where a complete clinical remission was documented in a patient
undergoing Rexin-G treatment as stand-alone therapy in an ongoing U.S. Phase
I/II clinical trial.

According to Erlinda Maria Gordon, M.D., Medical Director of Epeius Biotech,
"It is gratifying to learn that more and more eminent medical oncologists
around the world are recommending Rexin-G as 'Best Care' for patients with
refractory metastatic disease, and even more gratifying to show how truly
effective Rexin-G at these doses can be in eradicating such difficult
cancers." Indeed, as the unprecedented single-agent efficacy of Rexin-G is
incontrovertibly demonstrated in an increasing number of chemo-resistant
cancers, the progressive steps of these intrepid pioneers may provide a
rational basis of hope and expectation for many when standard therapy has
failed. Rexin-G is approved for the treatment of all solid tumors in the
Philippines, and has been granted both Orphan Drug Status for pancreas cancer,
osteosarcoma and soft tissue sarcoma, and Fast Track Designation for pancreas
cancer by the U.S. FDA.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical
company dedicated to the advancement of genetic medicine with the development
and commercialization of its proprietary targeted delivery systems. To learn
more about our pipeline of proprietary biotechnologies currently available for
clinical development and/or new product development, please visit us at
http://www.epeiusbiotech.com.

*(Logo Link: Send2Press.com/mediaboom/09-1012-EpeiusBio_300dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R),
a unit of Neotrope(R). http://www.Send2Press.com

Note to editors:
Additional Epeius news/RSS:
http://profiles.send2press.com/Epeius_Biotechnologies.shtml

SOURCE Epeius Biotechnologies Corporation

Erlinda M. Gordon, M.D. of Epeius Biotechnologies Corporation,
+1-626-441-6695, egordon@epeiusbiotech.com